DermBiont

DermBiont, Inc. is a Boston, Massachusetts clinical-stage dermatology therapeutics company founded in 2017 that develops targeted topical treatments addressing the root cause of skin disease rather than its symptoms. Its lead program SM-030 is a first-in-class topical PKC-beta inhibitor in development for melasma and other hyperpigmentation disorders of the skin, targeting excess melanin production; earlier programs included SM-020 for seborrheic keratosis and the live-bacterial DBI-001 and DBI-002 candidates for atopic dermatitis, tinea pedis and onychomycosis. The company describes an in-house discovery platform for microbiome-based therapeutics built on terabytes of DNA sequencing data from human skin samples across healthy individuals and patients, paired with a proprietary computational biology platform that identifies functions gained and lost by the skin microbiome. That computational platform is internal research tooling, not a product: DermBiont sells drug candidates and partnering opportunities, publishes no developer program, no public API, no SDK and no machine-readable API contract of any kind, and its website is a Squarespace-hosted corporate site.

DermBiont is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Dermatology, and Therapeutics.

DermBiont’s developer surface includes support and 11 more developer resources.

🌐 Visit website 📡 Source on GitHub
6.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsDermatologyTherapeuticsSkin MicrobiomeMicrobiomeDrug DiscoveryClinical StageLife SciencesHealth

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 6.7/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.7 / 17
Commercial Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/dermbiont: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Dermbiont Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact
Contact
 Support
Support

Company 4

The organization behind the API

Website
Website
 About
About
 LinkedIn
LinkedIn
 Crunchbase
Crunchbase

Other 4

Properties that don't map to a standard resource type

Product
Product
 Platform
Platform
 Pipeline
Pipeline
 Leadership
Leadership

Source (apis.yml)

apis.yml Raw ↑ 
aid: dermbiont
name: DermBiont
description: 'DermBiont, Inc. is a Boston, Massachusetts clinical-stage dermatology therapeutics company founded in 2017 that
  develops targeted topical treatments addressing the root cause of skin disease rather than its symptoms. Its lead program
  SM-030 is a first-in-class topical PKC-beta inhibitor in development for melasma and other hyperpigmentation disorders of
  the skin, targeting excess melanin production; earlier programs included SM-020 for seborrheic keratosis and the live-bacterial
  DBI-001 and DBI-002 candidates for atopic dermatitis, tinea pedis and onychomycosis. The company describes an in-house discovery
  platform for microbiome-based therapeutics built on terabytes of DNA sequencing data from human skin samples across healthy
  individuals and patients, paired with a proprietary computational biology platform that identifies functions gained and
  lost by the skin microbiome. That computational platform is internal research tooling, not a product: DermBiont sells drug
  candidates and partnering opportunities, publishes no developer program, no public API, no SDK and no machine-readable API
  contract of any kind, and its website is a Squarespace-hosted corporate site.'
image: https://static1.squarespace.com/static/5be33300f93fd46b40da5761/t/629e316bea93f12ec9cc272d/1654534507403/DM-main-logo.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/dermbiont/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Dermatology
- Therapeutics
- Skin Microbiome
- Microbiome
- Drug Discovery
- Clinical Stage
- Life Sciences
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/dermbiont-domain-security.yml
- type: Website
  url: https://www.dermbiont.com/
- type: About
  url: https://www.dermbiont.com/overview
- type: Product
  url: https://www.dermbiont.com/platform
- type: Platform
  url: https://www.dermbiont.com/dermatology-platform
- type: Pipeline
  url: https://www.dermbiont.com/pipeline
- type: Leadership
  url: https://www.dermbiont.com/leadership
- type: Contact
  url: https://www.dermbiont.com/contact-us
- type: Support
  url: https://www.dermbiont.com/contact-us
- type: LinkedIn
  url: https://www.linkedin.com/company/dermbiont
- type: Crunchbase
  url: https://www.crunchbase.com/organization/dermbiont
- type: LLMsTxt
  url: llms/dermbiont-llms.txt
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: DermBiont is a clinical-stage dermatology drug developer whose only product is the SM-030 topical candidate; its
    sole web property is a 30-page Squarespace corporate site with no developer, docs or API section anywhere in its sitemap,
    every OpenAPI, GraphQL, llms.txt and .well-known path returns 404, api.dermbiont.com does not resolve, and no GitHub organization
    or first-party package exists on any public registry.
  evidence:
  - url: https://www.dermbiont.com/openapi.json
    status: 404
  - url: https://www.dermbiont.com/graphql
    status: 404
  - url: https://www.dermbiont.com/llms.txt
    status: 404
  - url: https://www.dermbiont.com/.well-known/agent-card.json
    status: 404
  - url: https://www.dermbiont.com/.well-known/agent.json
    status: 404
  - url: https://www.dermbiont.com/.well-known/security.txt
    status: 404
  - url: https://api.github.com/orgs/dermbiont
    status: 404
  - url: https://www.dermbiont.com/sitemap.xml
    status: 200
  checked: '2026-08-12'